AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01828788
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00359190
Drug: lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GW572016 ditosylate salt (lapatinib) will be given as 250 mg tablets via oral route
Trial: NCT00103051
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00103051
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00103051
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02179918
Drug: PF-05082566
RxNorm normalized name: PF-05082566
DrugBank: Utomilumab (DB15113)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting dose of 0.45 mg/kg q3wks IV, dose escalation
Trial: NCT00690235
Drug: Pramlintide
RxNorm normalized name: Pramlintide
DrugBank: Pramlintide (DB01278)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180mg subcutaneous injections, twice daily
Trial: NCT01117857
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.
Trial: NCT02074163
Drug: Gadolinium
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
Trial: NCT01065012
Drug: Udenafil 50 mg
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Trial: NCT01065012
Drug: Udenafil 100 mg
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Trial: NCT01065012
Drug: Udenafil 150 mg
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Trial: NCT01065012
Drug: Placebo Matching 50 mg Udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Trial: NCT02074163
Drug: Gadolinium
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
Trial: NCT02074163
Drug: Efficacy of Botox intramuscularly at Week 6
RxNorm normalized name: Botox
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Trial: NCT02074163
Drug: Efficacy of Botox intramuscularly at Week 12
RxNorm normalized name: Botox
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Trial: NCT02074163
Drug: Efficacy of Botox intramuscularly at Week 18
RxNorm normalized name: Botox
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Trial: NCT02074163
Drug: Efficacy of Botox intramuscularly at Week 24,
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Trial: NCT02074163
Drug: Efficacy of Botox intramuscularly at Week 30
RxNorm normalized name: Botox
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Trial: NCT02074163
Drug: Efficacy of Botox subdermally at Week 6
RxNorm normalized name: Botox
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Trial: NCT02074163
Drug: Efficacy of Botox subdermally at Week 12
RxNorm normalized name: Botox
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Trial: NCT02074163
Drug: Efficacy of Botox subdermally at Week 18
RxNorm normalized name: Botox
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Trial: NCT02074163
Drug: Efficacy of Botox subdermally at Week 24
RxNorm normalized name: Botox
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Trial: NCT01065012
Drug: Placebo Matching 100 mg Udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Trial: NCT02074163
Drug: Efficacy of Botox subdermally at Week 30
RxNorm normalized name: Botox
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
Trial: NCT01065012
Drug: Placebo Matching 150 mg Udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Trial: NCT02074163
Drug: Adverse Reactions of Botox intramuscularly
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
Trial: NCT00513994
Drug: Nitroglycerin
RxNorm normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP
Trial: NCT00343798
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00343798
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00343798
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV or PO
Trial: NCT00688688
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT00688688
Drug: Tolterodine
RxNorm normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended release capsules
Trial: NCT00688688
Drug: Placebo to Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching mirabegron placebo tablets.
Trial: NCT00688688
Drug: Placebo to Tolterodine
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching tolterodine placebo capsules.
Trial: NCT02253940
Drug: BILR 355 - Treatment A (current tablet formulation)
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02253940
Drug: BILR 355 - Treatment D (current tablet formulation)
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253940
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01024101
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
Trial: NCT02074163
Drug: Adverse Reactions of Botox subdermally
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
Trial: NCT02820688
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02439164
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used
Trial: NCT00003261
Drug: zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03366246
Drug: Lidocaine / Prilocaine Cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: according randomized this side received placebo or active product
Trial: NCT02820688
Drug: Bupivacaine 0.167%
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02820688
Drug: Bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02820688
Drug: Prilocaine 0.66%
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02820688
Drug: Prilocaine 0.5%
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03682354
Drug: Intercostal Nerve Block with PCIA
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intercostal nerve block consists in the injection of Ropivacaine (4 ml,0.5%) in related intercostal spaces. Patient-controlled intravenous analgesia regimen is conducted with sufentanil.
Trial: NCT03682354
Drug: Erector Spinae Plane Block (ESPB)
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erector Spinae Plane Block consists in the injection of Ropivacaine (20ml, 0.5%), in the anatomical plane between the Erector Spinae muscles and transverse process, laterally to the spinous process of T5 . The catheter was inserted and secured in place under ecographic guidance, and a patient-controlled regional anesthesia regimen was conducted with 0.2% ropivacaine.
Trial: NCT00525057
Drug: Dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given SC
Trial: NCT04572893
Drug: danicamtiv
RxNorm normalized name: Danicamtiv
DrugBank: Danicamtiv (DB18962)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myosin activator
Trial: NCT01492959
Drug: insulin human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment
Trial: NCT00982345
Drug: quetiapine (Seroquel XR)
RxNorm normalized name: quetiapine Extended Release Oral Tablet [Seroquel]
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.
Trial: NCT05357196
Drug: PT-112
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: PT-112, The MTD(Maximum Tolerated Dose ) and RP2D of PT-112 when used in combination with gemcitabine will be determined during dose escalation.~Drug: Gemcitabine, Gemcitabine will be administered at a fixed dose of 1000 mg.
Trial: NCT01805323
Drug: Dexamethasone Intravitreal Implant
RxNorm normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone Intravitreal Implant (OZURDEX®) previously administered according to general clinical practice.
Trial: NCT03329885
Drug: BMS-986251
RxNorm normalized name: BMS-986251
DrugBank: BMS-986251 (DB19007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating oral dose
Trial: NCT02762253
Drug: Riboflavin drops
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2
Trial: NCT00236626
Drug: topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00478959
Drug: Lenalidomide (Revlimid®)
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25mg PO daily for 21 out of 28days per cycle
Trial: NCT01111890
Drug: Azarga (brinzolamide 1% / timolol 0.5%)
RxNorm normalized name: Brinzolamide
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
Trial: NCT01111890
Drug: Cosopt (dorzolamide 2% / timolol 0.5%)
RxNorm normalized name: dorzolamide / timolol Ophthalmic Solution [Cosopt]
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
Trial: NCT00471211
Drug: PBT2
RxNorm normalized name: Clioquinol
DrugBank: Clioquinol (DB04815)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02775617
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.
Trial: NCT02775617
Drug: Permethrin
RxNorm normalized name: Permethrin
DrugBank: Permethrin (DB04930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.
Trial: NCT02049437
Drug: tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
Trial: NCT00747825
Drug: 131-I-MIP-1145
RxNorm normalized name: MIP-1095 I-131
DrugBank: MIP-1095 I-131 (DB14978)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV injection between 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145
Trial: NCT00752310
Drug: Darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01836653
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Trial: NCT01836653
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Trial: NCT00740519
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
Trial: NCT01836653
Drug: L-OHP
RxNorm normalized name: L-OHP
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Trial: NCT01836653
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Trial: NCT01836653
Drug: 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
Trial: NCT01845220
Drug: Broccoli Sprout Extract
RxNorm normalized name: broccoli sprout extract
DrugBank: Broccoli (DB10511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 nanomol of sulforaphane/cm2 of skin in 80% acetone for 3 applications on 3 successive days prior to alcohol challenge
Trial: NCT01096095
Drug: Sodium Phenylbutyrate
RxNorm normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powdered sodium phenylbutyrate in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets) and may be reduced in case of mild adverse events.
Trial: NCT00990756
Drug: PF-03526299
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dry powder for inhalation, 1.396 mg, BID for 14 days
Trial: NCT00990756
Drug: PF-03526299
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dry powder for inhalation, 4 mg, BID for 14 days
Trial: NCT00297765
Drug: Tacrolimus, Prograf®
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00510367
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2 By Vein Daily x 2 Days
Trial: NCT00000195
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01444976
Drug: local anesthesia
RxNorm normalized name: Esters of benzoic acid for local anesthesia
DrugBank: Benzoic acid (DB03793)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive only topical anesthesia with 1% lidocaine
Trial: NCT01444976
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Before insertion of the probe, the patients will be sedated with midazolam at a dose of 0,.05 mg/kg iv (to achieve a Ramsay Sedation Score of 2-3). If needed, additional iv doses (0.005 mg/kg) were given during the procedure.
Trial: NCT02096003
Drug: Intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.
Trial: NCT02096003
Drug: Intrathecal hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.
Trial: NCT02788591
Drug: Sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject will take Sucralfate 4 times a day for 8 weeks.
Trial: NCT01084330
Drug: AUY922
RxNorm normalized name: AUY922
DrugBank: AUY922 (DB11881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70mg/m2
Trial: NCT01084330
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2
Trial: NCT01084330
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Iriniotecan 350mg/m2
Trial: NCT00147654
Drug: Tamsulosin 0.4 mg QD
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no